BM-573, a Dual Thromboxane Synthase Inhibitor and Thromboxane Receptor Antagonist, Prevents Pig Myocardial Infarction Induced by Coronary Thrombosis
暂无分享,去创建一个
M Petein | P. Kolh | B. Lambermont | B. Masereel | S. Rolin | J. Dogné | A. Ghuysen | P Kolh | B Masereel | M. Pétein | S Rolin | V Tchana-Sato | J M Dogne | P Benoit | B Lambermont | A Ghuysen | V. Tchana-Sato | P. Benoit
[1] H. A. Friedel,et al. Torasemide. A review of its pharmacological properties and therapeutic potential. , 1991, Drugs.
[2] P. Janssen,et al. R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - II. Pharmacological Effects In Vivo and Ex Vivo , 1989, Thrombosis and Haemostasis.
[3] R. N. Brogden,et al. Enoximone. A review of its pharmacological properties and therapeutic potential. , 1991, Drugs.
[4] L Roy,et al. Platelet activation in unstable coronary disease. , 1986, The New England journal of medicine.
[5] K. R. Anderson,et al. An experimental assessment of macroscopic enzyme techniques for the autopsy demonstration of myocardial infarction , 1979, The Journal of pathology.
[6] T. Pearson,et al. The human atherosclerotic plaque. , 1977, The American journal of pathology.
[7] Z. Ruggeri. New insights into the mechanisms of platelet adhesion and aggregation. , 1994, Seminars in hematology.
[8] R. Reneman,et al. Early myocardial ischaemia: evaluation of the histochemical haematoxylin-basic fuchsin-picric acid (HBFP) staining technique. , 1976, Cardiovascular research.
[9] E. Braunwald,et al. Myocardial ischemia (first of three parts). , 1977, The New England journal of medicine.
[10] J. Vermylen,et al. BM 13.177, A SELECTIVE BLOCKER OF PLATELET AND VESSEL WALL THROMBOXANE RECEPTORS, IS ACTIVE IN MAN , 1984, The Lancet.
[11] A. M. Lefer,et al. Prevention of extension of ischaemic damage following acute myocardial ischaemia by dazoxiben, a new thromboxane synthetase inhibitor. , 1983, British journal of clinical pharmacology.
[12] R. Kloner,et al. Early ischemic ultrastructural and histochemical alterations in the myocardium of the rat following coronary artery occlusion. , 1979, Experimental and molecular pathology.
[13] L. Hillis,et al. Effects of provocation on transcardiac thromboxane in patients with coronary artery disease. , 1983, The American journal of cardiology.
[14] H. Kido,et al. A novel loop diuretic, torasemide, inhibits thromboxane A2-induced contraction in the isolated canine coronary artery. , 1992, Prostaglandins, leukotrienes, and essential fatty acids.
[15] D. Warltier,et al. Determination of experimental myocardial infarct size. , 1981, Journal of pharmacological methods.
[16] J. Vane,et al. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. , 1978, Pharmacological reviews.
[17] H. Okuyama,et al. Effect of dietary alpha-linolenate/linoleate balance on collagen-induced platelet aggregation and serotonin release in rats. , 1989, Chemical & pharmaceutical bulletin.
[18] B. Masereel,et al. Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles. , 2001, Prostaglandins, leukotrienes, and essential fatty acids.
[19] K. Kubo,et al. Early thrombolysis by recombinant tissue-plasminogen activator is beneficial to the ischemic myocardium. , 1992, Journal of pharmacobio-dynamics.
[20] A. M. Lefer,et al. Anti-ischemic actions of a new thromboxane receptor antagonist, SQ-29,548, in acute myocardial ischemia. , 1986, European journal of pharmacology.
[21] V. Nachmias,et al. Platelet activation. , 2020, Arteriosclerosis.
[22] B. Masereel,et al. Thromboxane A2 Receptor Antagonism in Man and Rat by a Sulphonylcyanoguanidine (BM‐144) and a Sulphonylurea (BM‐500) , 1999, The Journal of pharmacy and pharmacology.
[23] P. Pairolero,et al. Macroscopic enzyme-mapping verification of large, homogeneous, experimental myocardial infarcts of predictable size and location in dogs. , 1975, The Journal of thoracic and cardiovascular surgery.
[24] M. Fishbein,et al. Early phase acute myocardial infarct size quantification: validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. , 1981, American heart journal.
[25] P. Janssen,et al. R 68 070: Thromboxane A2 Synthetase Inhibition and Thromboxane A2/Prostaglandin Endoperoxide Receptor Blockade Combined in One Molecule - I. Biochemical Profile In Vitro , 1989, Thrombosis and Haemostasis.
[26] M. Sekiguchi,et al. Coronary thrombosis in pathogenesis of acute myocardial infarction. Histopathological study of coronary arteries in 108 necropsied cases using serial section. , 1978, British heart journal.
[27] A. M. Lefer,et al. Preservation of ischemic myocardium by pinane thromboxane A2. , 1980, The American journal of physiology.
[28] G. Sandusky,et al. Rat model of arterial thrombosis induced by ferric chloride. , 1990, Thrombosis research.
[29] M. Nachlas,et al. Macroscopic identification of early myocardial infarcts by alterations in dehydrogenase activity. , 1963, The American journal of pathology.
[30] P. J. Simpson,et al. Prostacyclin protects ischemic reperfused myocardium in the dog by inhibition of neutrophil activation. , 1987, American heart journal.
[31] F. Schoen,et al. Pathologic detection of early myocardial infarction: a critical review of the evolution and usefulness of modern techniques. , 1999, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[32] L. Hillis,et al. Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. , 1981, The New England journal of medicine.
[33] S. Rolin,et al. Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function. , 2000, Prostaglandins, leukotrienes, and essential fatty acids.
[34] M. Brezinski,et al. Cardioprotective Actions of Specific Thromboxane Receptor Antagonist in Acute Myocardial Ischemia , 1987, Journal of cardiovascular pharmacology.
[35] K. Okumura,et al. Myocardial salvage by a novel thromboxane A2 synthetase inhibitor in a canine coronary occlusion-reperfusion model. , 1988, Arzneimittel-Forschung.
[36] M. Hamberg,et al. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. , 1975, Proceedings of the National Academy of Sciences of the United States of America.
[37] Wolfgang Koenig,et al. Inflammation and Coronary Heart Disease: An Overview , 2001, Cardiology in review.
[38] B. Strauer,et al. Cardiac troponin T in patients with clinically suspected myocarditis. , 1997, Journal of the American College of Cardiology.
[39] G. Majno,et al. Histopathology of early myocardial infarcts. A new approach. , 1974, The American journal of pathology.
[40] J. Wouters,et al. Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor , 2001, The Journal of pharmacy and pharmacology.